Soleno Therapeutics Acquired by Neurocrine Biosciences | Healthcare M&A Deal

Neurocrine Biosciences has acquired Soleno Therapeutics, a pharmaceuticals business in California, for $53.00 per share. Soleno Therapeutics develops pharmaceutical therapies, and the Soleno Therapeutics acquisition expands Neurocrine Biosciences acquisitions in healthcare M&A. The merger acquisition is structured through Sigma Merger Sub, Inc., a wholly owned subsidiary of Neurocrine Biosciences, targeting CA acquisitions. The strategic acquisition is an announced tender offer merger acquisition with over $100M deal size, and the cash consideration is subject to withholding taxes. Amendment No. 1 to the SEC Schedule TO reflects the cross-border tender offer process for the pharmaceuticals acquisition.